Dexmethylphenidate

What it is

Dexmethylphenidate is a central nervous system stimulant used for attention-deficit/hyperactivity disorder. It is the single active mirror-image form (the d-threo enantiomer) of methylphenidate, so a given milligram dose is roughly twice as potent as the same dose of ordinary racemic methylphenidate. In the United States it is a Schedule II controlled substance and carries a boxed warning for abuse, misuse and addiction. Only about a quarter of a swallowed dose reaches the bloodstream intact.

What the research says

Short-term randomised trials show a clear reduction in ADHD symptom scores against placebo, and a randomised withdrawal study found treatment failure in 17.1% of children kept on the drug versus 62.5% of those switched to placebo. The 2025 Cochrane review of methylphenidate rates the whole evidence base as very low certainty because nearly every trial is at high risk of bias, found no effect on quality of life, and found more non-serious adverse events on drug. Dexmethylphenidate was not shown to be better than ordinary methylphenidate, only equally effective at half the milligram dose. It produces physical dependence, tolerance and a withdrawal syndrome.

Evidence grade: Well established.

How it works

Drug class: Central nervous system stimulant; d-threo enantiomer of methylphenidate; Schedule II controlled substance in the United States

It is a central nervous system stimulant and is the more pharmacologically active d-enantiomer of racemic methylphenidate. The label states that methylphenidate blocks the reuptake of noradrenaline and dopamine into the nerve cell that released them and increases the release of these chemical messengers into the space between cells, so more of them are available there. Section 12.1 of the same label says the mode of therapeutic action in ADHD is not known. (Source 1)

Boxed warning

Focalin has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including Focalin, can result in overdose and death [see Overdosage (10)], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.

(Source 2)

What it is used for

• A meta-analysis of randomised trials in 1,124 children and adolescents found dexmethylphenidate clearly better than placebo on symptom scales (SMD -1.20 in a laboratory school setting), and a randomised withdrawal study in the label found treatment failure in 17.1% on drug versus 62.5% on placebo. The 2025 Cochrane review of methylphenidate rates certainty for all outcomes as very low and found no effect on quality of life. Evidence: established. (Source 3)
• One randomised, double-blind, placebo-controlled trial in 154 patients found improvement in a fatigue score at 8 weeks (P=0.02) but no improvement in cognitive function, at the cost of drug-related adverse events in 63% versus 28% on placebo. A single trial is not a literature. Evidence: limited. (Source 4)

Interactions

• Alcohol (pharmacokinetic study): Alcohol raises the blood level of the active drug and strengthens its stimulant effect. In a 14-person crossover study ethanol increased peak dexmethylphenidate concentration by 27% and 4-to-8-hour exposure by 20%; with immediate-release products the reported rise is about 15%. (Source 5)
• Alcohol (effect on subjective stimulant response) (pharmacokinetic study): Alcohol taken before or after methylphenidate raised peak blood levels of the active enantiomer by about 40% and area under the curve by about 25% in 20 healthy volunteers, and women reported a greater subjective drug effect than men despite lower average plasma levels. This is a single small crossover pharmacokinetic study, and the sex comparison was a subjective rating, not a clinical outcome. (Source 6)
• Monoamine oxidase inhibitors (label): The combination can cause a hypertensive crisis, with outcomes listed including death, stroke, myocardial infarction and aortic dissection. It is contraindicated, including within 14 days of stopping an MAOI. (Source 7)
• Blood pressure medicines (label): Because the stimulant itself raises blood pressure, it can work against drugs prescribed to lower it, and the label advises adjusting the antihypertensive dose as needed. (Source 8)
• Food (a high-fat meal) (pharmacokinetic study): Food does not change how much drug gets into the blood from the immediate-release tablet, but it slows the peak by about an hour and a half. The label permits dosing with or without food. (Source 9)
• Risperidone (case reports): Changing the dose of either drug, up or down, while the two are combined may raise the risk of extrapyramidal movement side effects. (Source 10)
• Halogenated anaesthetics (general anaesthesia on the day of surgery) (label): Having the stimulant on board during anaesthesia with a halogenated agent may bring a sudden rise in blood pressure and heart rate during surgery. The label says to monitor blood pressure and to avoid the drug on the day of surgery in anyone being given these anaesthetics. (Source 11)

Stopping it

• Dexmethylphenidate produces physical dependence, and abrupt stopping or a large dose cut after prolonged use brings a defined withdrawal syndrome: low or depressed mood, fatigue, vivid unpleasant dreams, disturbed sleep, increased appetite, and either slowed or agitated movement. (Source 12)
• Tolerance can also develop, meaning a larger dose comes to be needed for the same effect, which is one reason dose reduction rather than escalation is sometimes the right move. (Source 12)
• The label's own stopping rules are to reduce the dose or discontinue if symptoms paradoxically worsen or other adverse reactions appear, and to discontinue if there is no improvement after appropriate dose adjustment over a month. (Source 13)
• Stopping also brings back the underlying symptoms in most people who were responding: in the label's randomised withdrawal study, 62.5% of children switched to placebo met the treatment-failure definition within two weeks, against 17.1% kept on the drug. The label is internally inconsistent about who those children were, since Table 4 says ages 6 to 17 while the text of the same section says 75 children aged 6 to 12. (Source 14)
• Growth suppression is one harm the label suggests is handled by interrupting treatment: it instructs close monitoring of weight and height, and says children not growing as expected may need treatment interrupted. (Source 15)

What goes wrong

The U.S. boxed warning states that dexmethylphenidate has a high potential for abuse and misuse that can lead to a substance use disorder including addiction, and that misuse and abuse of stimulants can result in overdose and death. (Source 2)

• Official position, Certainty not rated.
• Size: not applicable.
• Who: Anyone prescribed dexmethylphenidate.
• How long: not applicable.
• Result: No rate is given in the boxed warning; it is a regulatory position on the label dated 30 May 2024, and the drug is a Schedule II controlled substance.
• Funding: not stated.

Focalin has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including Focalin, can result in overdose and death [see Overdosage (10)], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.

Dexmethylphenidate produces physical dependence and tolerance, with a named withdrawal syndrome after abrupt stopping or a large dose reduction following prolonged use. (Source 12)

• Official position, Certainty not rated.
• Size: not applicable.
• Who: People who have taken CNS stimulants including dexmethylphenidate for a prolonged period.
• How long: not applicable.
• Result: No incidence figures are given; the withdrawal syndrome listed is dysphoric mood, depression, fatigue, vivid unpleasant dreams, insomnia or hypersomnia, increased appetite, and psychomotor retardation or agitation.
• Funding: not stated.

Withdrawal signs and symptoms after abrupt discontinuation or dose reduction following prolonged use of CNS stimulants including Focalin include dysphoric mood; depression; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation.

The 2025 Cochrane review found methylphenidate may cause more non-serious adverse events than placebo, a 23% relative increase, on very low certainty evidence. (Source 16)

• Systematic review, Very low certainty.
• Size: 35 trials, 5,342 participants.
• Who: Children and adolescents with ADHD.
• How long: short-term trials, mean 28.8 days.
• Result: Non-serious adverse events RR 1.23 (95% CI 1.11 to 1.37), I squared 72%; trial sequential analysis adjusted RR 1.22 (1.08 to 1.43)
• Funding: mixed; 41% of included trials industry-funded.

methylphenidate may cause more adverse events considered non-serious versus placebo or no intervention (RR 1.23, 95% CI 1.11 to 1.37; I² = 72%; 35 trials 5342 participants; very low-certainty evidence).

In non-randomised comparative studies, methylphenidate was associated with more serious adverse events, more psychotic disorder and more arrhythmia than no treatment. (Source 17)

• Cohort study, Very low certainty.
• Size: 7 comparative cohort studies and 4 patient-control studies among 260 included studies; the largest comparison covered 72,005 participants.
• Who: Children and adolescents aged 3 to 20 with ADHD.
• How long: varied; non-randomised designs.
• Result: Serious adverse events RR 1.36 (95% CI 1.17 to 1.57, 2 studies, 72,005 participants); any psychotic disorder RR 1.36 (1.17 to 1.57, 71,771 participants); arrhythmia RR 1.61 (1.48 to 1.74, 1,224 participants)
• Funding: not stated.

Limit of this finding: The review reports exactly the same risk ratio and exactly the same confidence interval (1.36, 1.17 to 1.57) for two different outcomes measured in different numbers of people: serious adverse events in 2 studies of 72,005 participants and any psychotic disorder in 1 study of 71,771. Two different outcomes giving identical figures to two decimal places is almost certainly because one study dominates both estimates, or a reporting slip. Treat the two as one signal rather than two independent ones, and remember these are non-randomised studies the reviewers themselves rated at critical risk of bias and very low quality.

In the comparative studies, methylphenidate increased the risk ratio (RR) of serious adverse events (RR 1.36, 95% confidence interval (CI) 1.17 to 1.57; 2 studies, 72,005 participants); any psychotic disorder (RR 1.36, 95% CI 1.17 to 1.57; 1 study, 71,771 participants); and arrhythmia (RR 1.61, 95% CI 1.48 to 1.74; 1 study, 1224 participants) compared to no intervention.

Pooled non-comparative cohorts put common side effects at roughly one child in three for decreased appetite and one in six for trouble falling asleep, with the reviewers warning the real rates may be higher. (Source 18)

• Cohort study, Very low certainty.
• Size: up to 90 studies and 13,469 participants per outcome, within 260 included studies.
• Who: Children and adolescents on methylphenidate.
• How long: varied.
• Result: Decreased appetite 31.1% (95% CI 26.5% to 36.2%); difficulty falling asleep 17.9% (14.7% to 21.6%); headache 14.4% (11.3% to 18.3%); abdominal pain 10.7% (8.60% to 13.3%)
• Funding: not stated.

These included difficulty falling asleep, 17.9% (95% CI 14.7% to 21.6%; 82 studies, 11,507 participants); headache, 14.4% (95% CI 11.3% to 18.3%; 90 studies, 13,469 participants); abdominal pain, 10.7% (95% CI 8.60% to 13.3%; 79 studies, 11,750 participants); and decreased appetite, 31.1% (95% CI 26.5% to 36.2%; 84 studies, 11,594 participants).

Long-term methylphenidate taken every day of the year slowed growth by about 2 cm in height and 2.7 kg in weight over three years, without evidence of catch-up during that period. (Source 15)

• Cohort study, Low certainty.
• Size: not stated in this label section; naturalistic subgroups followed from ages 7-10 to ages 10-13.
• Who: Children randomised to methylphenidate or non-medication treatment over 14 months, then followed naturalistically to 36 months.
• How long: up to 36 months.
• Result: About 2 cm less growth in height and 2.7 kg less growth in weight over 3 years, without evidence of growth rebound during this development period.
• Funding: not stated (the MTA follow-up data as summarised on the label)

suggests that pediatric patients who received methylphenidate for 7 days per week throughout the year had a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this development period.

Dexmethylphenidate raises blood pressure and heart rate modestly on average, with larger rises in some people. (Source 19)

• Official position, Certainty not rated.
• Size: not applicable.
• Who: Patients treated with CNS stimulants including dexmethylphenidate.
• How long: not applicable.
• Result: Mean increase approximately 2 to 4 mmHg in blood pressure and approximately 3 to 6 beats per minute in heart rate.
• Funding: not stated.

CNS stimulants cause an increase in blood pressure (mean increase approximately 2 to 4 mmHg) and heart rate (mean increase approximately 3 to 6 beats per minute). Some patients may have larger increases.

About one child in fourteen stopped dexmethylphenidate in the premarketing programme because of a side effect, most often tics, loss of appetite, insomnia or fast heart rate. (Source 20)

• Randomized trial, Moderate certainty.
• Size: 684 ADHD patients aged 6 to 17 in the premarketing development programme.
• Who: Children and adolescents with ADHD across 2 controlled studies, 2 pharmacology studies and 2 open-label safety studies.
• How long: includes long-term open-label follow-up.
• Result: 50 of 684 (7.3%) discontinued for an adverse reaction; twitching, anorexia, insomnia and tachycardia each about 1%.
• Funding: not stated (manufacturer trial data reproduced on the label)

Adverse Reactions Leading to Discontinuation: Overall, 50 of 684 (7.3%) pediatric patients treated with Focalin experienced an adverse reaction that resulted in discontinuation. The most common reasons for discontinuation were twitching (described as motor or vocal tics), anorexia, insomnia, and tachycardia (approximately 1% each).

Drinking alcohol with dexmethylphenidate raises the blood level of the active drug and intensifies its stimulant effect, a human pharmacokinetic interaction rather than a theoretical one. (Source 5)

• Blood level study, Moderate certainty.
• Size: 14 healthy subjects in a randomised 4-way crossover study.
• Who: Healthy adult volunteers.
• How long: single-dose crossover sessions.
• Result: Ethanol raised d-MPH Cmax by 27% (P=0.001) and partial AUC from 4 to 8 hours by 20% (P<0.01) for the enantiopure d-MPH formulation; with immediate-release products the stated increases are 22% for racemic and 15% for d-MPH.
• Funding: independent (NIAAA, NIDA, NCRR and NCATS of the NIH)

Ethanol increased the second pulse of d-MPH Cmax for dl-MPH by 35% (P < 0.01) and the partial area under the plasma concentration curve from 4 to 8 hours by 25% (P < 0.05). The respective values for enantiopure d-MPH were 27% (P = 0.001) and 20% (P < 0.01).

Postmarketing reports with methylphenidate products include rhabdomyolysis, anaphylaxis and angioedema; these are spontaneous reports whose frequency cannot be estimated. (Source 21)

• Case series, Very low certainty.
• Size: not applicable (spontaneous reports from a population of uncertain size)
• Who: People taking dexmethylphenidate after approval.
• How long: not applicable.
• Result: No rate can be calculated; the label states frequency cannot be reliably estimated and causality cannot be established from these reports.
• Funding: not stated.

Immune System Disorders: hypersensitivity reactions, such as angioedema, anaphylactic reactions

The label records that misuse and abuse of methylphenidate can produce a sympathomimetic reaction and also anxiety, psychosis, hostility, aggression and suicidal or homicidal ideation, and that misuse and abuse of the drug can end in overdose and death. (Source 22)

• Official position, Certainty not rated.
• Size: Not applicable (regulatory position; no denominator given)
• Who: People who misuse or abuse methylphenidate or other CNS stimulants.
• How long: Not stated.
• Result: No rates are given. The listed effects are increased heart rate, respiratory rate or blood pressure, sweating, dilated pupils, hyperactivity, restlessness, insomnia, decreased appetite, loss of coordination, tremors, flushed skin, vomiting and abdominal pain, plus anxiety, psychosis, hostility, aggression and suicidal or homicidal ideation; the risk of overdose and death is said to rise with higher doses and with snorting or injection.
• Funding: not stated (U.S. prescribing information)

Misuse and abuse of methylphenidate may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse.

Sudden death has been reported in people with structural cardiac abnormalities or other serious cardiac disease who were taking CNS stimulants at ordinary ADHD doses, and the label says to avoid dexmethylphenidate in them. (Source 23)

• Official position, Certainty not rated.
• Size: Not applicable (case reports summarised as a regulatory position; no denominator given)
• Who: People with structural cardiac abnormalities, cardiomyopathy, serious arrhythmia, coronary artery disease or other serious cardiac disease.
• How long: Not stated.
• Result: No rate is given. The label states the deaths occurred at the recommended ADHD dosage and directs that the drug be avoided in this group.
• Funding: not stated (U.S. prescribing information)

Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who were treated with CNS stimulants at the recommended ADHD dosage.

In a pooled analysis of short-term placebo-controlled stimulant trials reported on the label, psychotic or manic symptoms occurred in about 0.1% of stimulant-treated patients and in none on placebo, in people with no prior history of psychosis or mania. (Source 24)

• Official position, Certainty not rated.
• Size: Multiple short-term, placebo-controlled studies of CNS stimulants; the label gives no total.
• Who: Patients without a prior history of psychotic illness or mania.
• How long: Short-term placebo-controlled studies.
• Result: Psychotic or manic symptoms in approximately 0.1% of CNS stimulant-treated patients compared to 0% of placebo-treated patients, an absolute excess of about 1 in 1,000.
• Funding: not stated (U.S. prescribing information, pooling manufacturer trial data)

In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants, psychotic, or manic symptoms occurred in approximately 0.1% of CNS stimulant-treated patients, compared to 0% of placebo-treated patients.

What the evidence supports

Dexmethylphenidate reduced ADHD symptom scores substantially more than placebo across randomised trials, with large effect sizes on teacher and parent rating scales. (Source 3)

• Meta-analysis, Low certainty.
• Size: 1,124 children and adolescents across the included randomised controlled trials.
• Who: Children and adolescents up to 18 years with ADHD.
• How long: varied; includes laboratory school-day studies.
• Result: Laboratory school setting SMD -1.20 (95% CI -1.73 to -0.67), I(2)=95%; teacher rating scales weighted mean difference -13.01 (95% CI -15.97 to -10.05), I(2)=0%; parent scales -12.99 (95% CI -15.57 to -10.42)
• Funding: not stated.

In a laboratory school setting, the pooled mean-change and mean-endpoint scores in the d-MPH-treated group were significantly greater than those of the placebo-treated group with standardized mean difference (95% confidence interval [CI]) of -1.20 (-1.73, -0.67), I (2)=95%.

In a randomised withdrawal study, children taken off dexmethylphenidate after responding were far more likely to deteriorate: 62.5% treatment failure on placebo versus 17.1% on continued drug, an absolute difference of about 45 percentage points. (Source 14)

• Randomized trial, Moderate certainty.
• Size: 75 children randomised after a 6-week open-label run-in.
• Who: Children aged 6 to 12 who had responded to dexmethylphenidate.
• How long: 2-week double-blind withdrawal phase.
• Result: Treatment failure 6/35 (17.1%) on continued Focalin versus 25/40 (62.5%) on placebo; absolute difference about 45 percentage points, roughly 2 to 3 children treated to prevent one failure.
• Funding: not stated (manufacturer trial data reproduced on the label)

Limit of this finding: The label contradicts itself about this study. The caption of Table 4 says the patients were aged 6 to 17 years, while the text of the same section says Study 2 enrolled 75 children aged 6 to 12. The table's footnote also says one patient was left out of the analysis, yet its own denominators add up to every patient randomised (6 of 35 plus 25 of 40 is 75). Read the percentages as the label's own figures for children who had already responded to the drug; do not read them as applying to teenagers, and do not assume a patient was excluded.

Patients continued on Focalin showed a statistically significant lower rate of failure

The 2025 Cochrane review found methylphenidate may improve teacher-rated ADHD symptoms by about 10.6 points on a 72-point scale, above the 6.6-point threshold the reviewers treat as clinically relevant, but rated the certainty of that estimate as very low. (Source 25)

• Systematic review, Very low certainty.
• Size: 21 trials, 1,728 participants for the symptom outcome; 212 trials and 16,302 participants in the whole review.
• Who: Children and adolescents 18 years and younger with ADHD and IQ above 70.
• How long: mean treatment duration 28.8 days, range 1 to 425 days.
• Result: Teacher-rated symptoms SMD -0.74 (95% CI -0.88 to -0.61), I squared 38%, equivalent to a mean difference of -10.58 (95% CI -12.58 to -8.72) on the ADHD Rating Scale; minimal clinically relevant difference taken as 6.6 points.
• Funding: mixed; the review reports that 86 of 212 included trials (41%) were funded or partly funded by the pharmaceutical industry.

methylphenidate versus placebo or no intervention may improve teacher-rated ADHD symptoms (standardised mean difference (SMD) -0.74, 95% confidence interval (CI) -0.88 to -0.61; I² = 38%; 21 trials; 1728 participants; very low-certainty evidence). This corresponds to a mean difference (MD) of -10.58 (95% CI -12.58 to -8.72) on the ADHD Rating Scale (ADHD-RS; range 0 to 72 points). The minimal clinically relevant difference is considered to be a change of 6.6 points on the ADHD-RS.

In the first of the two pivotal trials on the U.S. label, children given dexmethylphenidate showed a statistically significant improvement in teacher-rated ADHD symptom scores over four weeks compared with placebo. (Source 26)

• Randomized trial, Moderate certainty.
• Size: 132 pediatric patients randomised across Focalin, racemic methylphenidate and placebo arms (Focalin n = 44, placebo n = 42)
• Who: Untreated or previously treated children meeting DSM-IV criteria for ADHD, predominantly aged 6 to 12.
• How long: 4 weeks.
• Result: Teacher SNAP-ADHD total score: Focalin 5-20 mg/day (n = 44) mean baseline 1.4 (SD 0.7), mean change -0.7 (0.7); placebo (n = 42) mean baseline 1.6 (0.7), mean change -0.2 (0.7) on a 0 to 3 scale.
• Funding: not stated (manufacturer trial data reproduced on the label)

Limit of this finding: This is a four-week trial of rated symptoms, reported on the manufacturer's own label. A 0.5-point change on a 0 to 3 teacher rating scale is a change in how symptoms were scored while the drug was being taken; it is not evidence about school results, long-term outcome, or the underlying condition.

Patients treated with Focalin showed a statistically significant improvement in symptom scores from baseline over patients who received placebo (Table 3).

What the evidence does not support

The same Cochrane review found no effect of methylphenidate on quality of life, on very low certainty evidence. (Source 16)

• Systematic review, Very low certainty.
• Size: 4 trials, 608 participants.
• Who: Children and adolescents with ADHD.
• How long: short-term trials, mean 28.8 days.
• Result: Quality of life SMD 0.40 (95% CI -0.03 to 0.83), I squared 81%, very low-certainty evidence.
• Funding: mixed; 41% of included trials industry-funded.

but may not affect quality of life (SMD 0.40, 95% CI -0.03 to 0.83; I² = 81%; 4 trials, 608 participants; very low-certainty evidence).

Randomised trials did not show an increase in serious adverse events with methylphenidate, but the confidence interval is wide enough to include substantial harm and the certainty is very low. (Source 25)

• Systematic review, Very low certainty.
• Size: 26 trials, 3,673 participants.
• Who: Children and adolescents with ADHD.
• How long: short-term trials.
• Result: Serious adverse events RR 0.80 (95% CI 0.39 to 1.67), I squared 0%; trial sequential analysis adjusted RR 0.91 (0.31 to 2.68)
• Funding: mixed; 41% of included trials industry-funded.

Methylphenidate may not affect serious adverse events

Dexmethylphenidate was not shown to be better than ordinary racemic methylphenidate; at half the milligram dose it was equally effective and equally safe, and the claimed longer duration of action was not established. (Source 27)

• Randomized trial, Moderate certainty.
• Size: 132 children (d-MPH n=44, racemic methylphenidate n=46, placebo n=42)
• Who: Children with DSM-IV ADHD at 12 United States centres.
• How long: 4 weeks, twice-daily dosing with weekly titration.
• Result: Average titrated dose 18.25 mg/day d-MPH versus 32.14 mg/day racemic methylphenidate; both improved teacher SNAP ratings versus placebo (p=.0004 and p=.0042); CGI-I improvement 67% versus 49%; the duration-of-action hypothesis was not confirmed statistically.
• Funding: not stated.

Thus, d-MPH and d,l-MPH appear to provide similar efficacy, and d-MPH may have longer duration of action after twice-daily dosing, but additional studies are needed to determine the statistical and clinical significance of this possibility.

Where the evidence is mixed

Nearly the entire randomised evidence base for methylphenidate is at high risk of bias, and the reviewers argue that unblinding by the drug's recognisable side effects puts all 212 trials at high risk. (Source 28)

• Systematic review, Very low certainty.
• Size: 212 trials, 16,302 participants randomised.
• Who: Children and adolescents 18 years and younger with ADHD.
• How long: mean 28.8 days of treatment.
• Result: 191 of 212 trials assessed at high risk of bias and 21 at low risk; counting deblinding by typical adverse events, all 212 at high risk; 86 of 212 (41%) industry funded.
• Funding: mixed; 41% of included trials industry-funded.

Of the 212 trials, we assessed 191 at high risk of bias and 21 at low risk of bias. If, however, deblinding of methylphenidate due to typical adverse events is considered, then all 212 trials were at high risk of bias.

The Cochrane reviewers state that the certainty of the evidence for every outcome in their review is very low, so the true size of both benefits and harms remains unclear. (Source 29)

• Systematic review, Very low certainty.
• Size: 212 trials, 16,302 participants.
• Who: Children and adolescents with ADHD.
• How long: short-term.
• Result: No effect estimate; this is the reviewers' overall GRADE statement.
• Funding: mixed; 41% of included trials industry-funded.

However, the certainty of the evidence for all outcomes is very low

For chemotherapy-related fatigue, a single randomised placebo-controlled trial found a fatigue-score benefit but no cognitive benefit, and more than twice the rate of drug-related adverse events. (Source 4)

• Randomized trial, Low certainty.
• Size: 154 patients randomised and treated.
• Who: Adults, predominantly with breast and ovarian cancer, with fatigue after cytotoxic chemotherapy.
• How long: 8 weeks.
• Result: FACIT-F fatigue score improved versus placebo (P=0.02) and CGI-Severity improved (P=0.02); cognitive function not significantly improved; drug-related adverse events 63% (48/76) versus 28% (22/78); discontinuation for adverse events 11% (8/76) versus 1.3% (1/78)
• Funding: not stated.

Compared with placebo, D-MPH-treated subjects demonstrated a significant improvement in fatigue symptoms at Week 8 in the FACIT-F (P=0.02) and the Clinical Global Impression-Severity scores (P=0.02), without clinically relevant changes in hemoglobin levels. Cognitive function was not significantly improved. There was a higher rate of study drug-related adverse events (AEs) (48 of 76 [63%] vs. 22 of 78 [28%]) and a higher discontinuation rate because of AEs (8 of 76 [11%] vs. 1 of 78 [1.3%]) in D-MPH-treated subjects compared with placebo-treated subjects.

The non-randomised evidence on methylphenidate harms that the 2018 Cochrane review pooled was almost entirely at critical risk of bias, and the reviewers rated the whole body of it very low quality. (Source 30)

• Systematic review, Very low certainty.
• Size: 260 non-randomised studies, including 177 non-comparative cohorts with 2,207,751 participants.
• Who: Children and adolescents with ADHD, ages 3 to 20 years.
• How long: Varied; not pooled.
• Result: Risk of bias in the comparative studies ranged from moderate to critical, with most at critical risk; all non-comparative studies were judged at critical risk of bias; GRADE quality of the evidence very low.
• Funding: independent (Cochrane review)

Risk of bias in the included comparative studies ranged from moderate to critical, with most studies showing critical risk of bias. We evaluated all non-comparative studies at critical risk of bias. The GRADE quality rating of the evidence was very low.

Where the research disagrees

How certain the benefit of methylphenidate-class stimulants in children actually is

• Storebo and colleagues, Cochrane review of methylphenidate, 2025 update, systematic review of 212 randomised trials with GRADE and trial sequential analysis: However, the certainty of the evidence for all outcomes is very low (Source 29)
• Cortese and colleagues, network meta-analysis of 133 trials (2018), systematic review and network meta-analysis: Taking into account both efficacy and safety, evidence from this meta-analysis supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD. (Source 31)

Whether dexmethylphenidate offers anything over ordinary racemic methylphenidate

• Wigal and colleagues, double-blind three-arm trial (2004), randomised, double-blind, placebo-controlled trial in 132 children: For the treatment of ADHD, an average titrated dose of 18.25 mg/day of d-MPH is as efficacious and safe as an average titrated dose of 32.14 mg/day of d,l-MPH. (Source 27)
• Maneeton and colleagues, meta-analysis of dexmethylphenidate versus placebo (2015), meta-analysis of randomised controlled trials, 1,124 participants: The rates of pooled overall discontinuation (Source 3)

How much

• Reference intake: There is no reference intake for a controlled stimulant; the dose is set and titrated by the prescriber. As a position, the U.S. label dated 30 May 2024 states a starting dose of 5 mg daily (2.5 mg twice daily) for pediatric patients new to methylphenidate. (Source 32)
• Upper limit: No tolerable upper intake level exists. The U.S. label dated 30 May 2024 states a maximum of 20 mg daily (10 mg twice daily) for the immediate-release tablets, titrated weekly in 2.5 to 5 mg increments. (Source 32)
• Studied: The two pivotal label trials gave Focalin 5, 10 or 20 mg per day total dose, divided twice daily, in children aged 6 to 17. (Source 20)
• Studied: The head-to-head trial against racemic methylphenidate titrated 132 children over 4 weeks to an average 18.25 mg/day of dexmethylphenidate versus 32.14 mg/day of racemic methylphenidate. (Source 33)
• Studied: The alcohol interaction study gave 20 mg of pulsatile dexmethylphenidate with or without ethanol 0.6 g/kg in 14 healthy volunteers. (Source 34)

A common belief, and what the research shows

The belief: Because it is prescribed to children and comes in tablets, a stimulant like dexmethylphenidate is not really an addictive drug, and you can just stop it whenever you like.

What the research shows: The label is unambiguous on both points. On abuse: "Focalin contains dexmethylphenidate hydrochloride, a Schedule II controlled substance." and the boxed warning states "Focalin has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction." On stopping: "Withdrawal signs and symptoms after abrupt discontinuation or dose reduction following prolonged use of CNS stimulants including Focalin include dysphoric mood; depression; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation."

Questions and answers

What is it?

Dexmethylphenidate is a prescription central nervous system stimulant for ADHD. Chemically it is one of the two mirror-image halves of methylphenidate, the active one, so the milligram doses are about half those of ordinary methylphenidate. In the United States it is a Schedule II controlled substance, the same legal category as morphine and amphetamine. (Source 35)

What does it do in the body?

It is a stimulant that increases the availability of dopamine and noradrenaline between nerve cells. The U.S. label does not pretend to know more than that: it states the mode of therapeutic action in ADHD is not known. What the trials show is a reduction in rated ADHD symptoms while the drug is in the body, not a change in the underlying condition. (Source 36)

Is it good or bad for you?

Both, and the balance is genuinely contested. In randomised withdrawal, 17.1% of children kept on it deteriorated versus 62.5% taken off it, and meta-analysis gives large effect sizes on symptom scales. But the 2025 Cochrane review rates the whole evidence base very low certainty, found no effect on quality of life, and found more non-serious side effects on drug; the label carries a boxed warning for abuse, misuse and addiction, and long-term daily use slowed growth by about 2 cm over three years. (Source 29)

How do you get more of it?

Dexmethylphenidate is a Schedule II controlled substance available only on prescription; there is no food, supplement or over-the-counter source. The prescriber sets and titrates the dose. As a position, the U.S. label dated 30 May 2024 states a 5 mg daily start for children new to methylphenidate, weekly increments of 2.5 to 5 mg, and a maximum of 20 mg daily for the immediate-release tablets. None of this is advice for any individual. (Source 32)

If it is harmful, what reduces it?

The drug itself leaves the body within hours, with an elimination half-life of about two hours for the immediate-release form. Where it is causing harm, the label's response is to reduce the dose or stop the drug. Stopping abruptly after prolonged use is not harmless: there is a recognised withdrawal syndrome of low mood, fatigue, disturbed sleep, vivid dreams and increased appetite, which is why dose reduction is usually managed rather than abrupt. (Source 13)

Why might someone be low in it or missing it?

Nobody is naturally deficient in dexmethylphenidate. Blood levels fall short of what was intended for two main reasons. First, most of a swallowed dose never reaches the circulation: first-pass metabolism leaves an absolute bioavailability of only 22% to 25%. Second, the immediate-release drug is gone quickly, so missed doses or a dosing gap across the afternoon leaves hours with no drug effect. (Source 37)

Which whole foods contain it or feed it?

No whole food contains dexmethylphenidate; it is a synthetic controlled substance. Food does interact with how the tablet behaves: a high-fat breakfast did not change how much drug was absorbed but pushed the peak back from 1.5 to 2.9 hours after the dose. Alcohol is the one dietary substance with a documented pharmacokinetic interaction, raising peak drug levels and stimulant effect. (Source 9)

What happens if you do not have it?

For most people, not taking it changes nothing. For someone with ADHD who had responded and then stops, the label's own randomised withdrawal study is the clearest answer: 62.5% of children switched to placebo met the treatment-failure definition within two weeks, against 17.1% of those kept on the drug. After prolonged use, abrupt absence also brings the withdrawal syndrome described in section 9.3. (Source 14)

How can you test for it?

There is no validated blood test for dexmethylphenidate levels in routine care, and no laboratory test diagnoses ADHD or confirms the drug is working; response is judged on rating scales such as the teacher SNAP used in the pivotal trials. Urine drug screens detect methylphenidate use but say nothing about dose adequacy. We searched Europe PMC for dexmethylphenidate therapeutic drug monitoring and found no validated monitoring assay in routine use; the label gives pharmacokinetic parameters but no monitoring target. (Source 37)

We searched: Europe PMC searches for dexmethylphenidate trials, meta-analyses and systematic reviews, plus the full FOCALIN prescribing information sections 12.3 Pharmacokinetics and 14 Clinical Studies; no validated therapeutic drug monitoring test or diagnostic assay was found

References

1. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - 12.2 Pharmacodynamics. 2024. Read the source
2. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - BOXED WARNING section. 2024. Read the source
3. Neuropsychiatric disease and treatment. Comparative efficacy, acceptability, and tolerability of dexmethylphenidate versus placebo in child and adolescent ADHD: a meta-analysis of randomized controlled trials.. 2015. PMID 26648726, DOI 10.2147/ndt.s91765. Read the source
4. Journal of pain and symptom management. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial.. 2009. PMID 19896571, DOI 10.1016/j.jpainsymman.2009.03.011. Read the source
5. Journal of clinical psychopharmacology. Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers.. 2017. PMID 28590363, DOI 10.1097/jcp.0000000000000721. Read the source
6. Clinical pharmacology and therapeutics. Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics.. 2007. PMID 17339864, DOI 10.1038/sj.clpt.6100082. Read the source
7. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - 7.1 Clinically Important Drug Interactions with Focalin, Table 2 (Monoamine Oxidase Inhibitors row). 2024. Read the source
8. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - 7.1 Clinically Important Drug Interactions with Focalin, Table 2 (Antihypertensive Drugs row). 2024. Read the source
9. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - 12.3 Pharmacokinetics (Effect of Food, Distribution). 2024. Read the source
10. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - 7.1 Clinically Important Drug Interactions with Focalin, Table 2 (Risperidone row). 2024. Read the source
11. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - 7.1 Clinically Important Drug Interactions with Focalin, Table 2 (Halogenated Anesthetics row). 2024. Read the source
12. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - 9.3 Dependence. 2024. Read the source
13. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - 2.4 Dosage Reduction and Discontinuation. 2024. Read the source
14. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - 14 CLINICAL STUDIES (Study 2 randomized withdrawal and Table 4). 2024. Read the source
15. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - 5.7 Long-Term Suppression of Growth in Pediatric Patients. 2024. Read the source
16. The Cochrane database of systematic reviews. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).. 2025. PMID 41342306, DOI 10.1002/14651858.cd009885.pub4. Read the source
17. The Cochrane database of systematic reviews. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.. 2018. PMID 29744873, DOI 10.1002/14651858.cd012069.pub2. Read the source
18. The Cochrane database of systematic reviews. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.. 2018. PMID 29744873, DOI 10.1002/14651858.cd012069.pub2. Read the source
19. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - 5.3 Increased Blood Pressure and Heart Rate. 2024. Read the source
20. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - 6.1 Clinical Trials Experience. 2024. Read the source
21. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - 6.2 Postmarketing Experience. 2024. Read the source
22. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - 9.2 Abuse. 2024. Read the source
23. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - 5.2 Risks to Patients with Serious Cardiac Disease. 2024. Read the source
24. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - 5.4 Psychiatric Adverse Reactions. 2024. Read the source
25. The Cochrane database of systematic reviews. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).. 2025. PMID 41342306, DOI 10.1002/14651858.cd009885.pub4. Read the source
26. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - 14 CLINICAL STUDIES (Study 1 titration, outcome and Table 3). 2024. Read the source
27. Journal of the American Academy of Child and Adolescent Psychiatry. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.. 2004. PMID 15502600, DOI 10.1097/01.chi.0000138351.98604.92. Read the source
28. The Cochrane database of systematic reviews. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).. 2025. PMID 41342306, DOI 10.1002/14651858.cd009885.pub4. Read the source
29. The Cochrane database of systematic reviews. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).. 2025. PMID 41342306, DOI 10.1002/14651858.cd009885.pub4. Read the source
30. The Cochrane database of systematic reviews. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies - section: Main results, risk of bias and certainty preamble. 2018. PMID 29744873, DOI 10.1002/14651858.cd012069.pub2. Read the source
31. The lancet. Psychiatry. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.. 2018. PMID 30097390, DOI 10.1016/s2215-0366(18)30269-4. Read the source
32. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - 2.2 Recommended Dosage. 2024. Read the source
33. Journal of the American Academy of Child and Adolescent Psychiatry. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.. 2004. PMID 15502600, DOI 10.1097/01.chi.0000138351.98604.92. Read the source
34. Journal of clinical psychopharmacology. Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers.. 2017. PMID 28590363, DOI 10.1097/jcp.0000000000000721. Read the source
35. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - 9.1 Controlled Substance. 2024. Read the source
36. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - 12.1 Mechanism of Action. 2024. Read the source
37. DailyMed (U.S. National Library of Medicine), Structured Product Label. FOCALIN (dexmethylphenidate hydrochloride) tablets - U.S. prescribing information - 12.3 Pharmacokinetics (Absorption). 2024. Read the source